ライフサイエンスコーパス: anti-tumor activity

1 beta-sheet peptide with anti-angiogenic and anti-tumor activity.

2 h various approaches, with a clear signal of anti-tumor activity.

3 describe surrogate endpoints correlated with anti-tumor activity.

4 al medicine and has been observed to contain anti-tumor activity.

5 In some instances it may also have direct anti-tumor activity.

6 strategies that are designed to augment TIL anti-tumor activity.

7 and tumor cell apoptosis and showed superior anti-tumor activity.

8 ibodies to OX40 and other TNFR with improved anti-tumor activity.

9 FcgammaR-binding capacity compromises their anti-tumor activity.

10 RF7/IFNbeta pathway was required for optimal anti-tumor activity.

11 idely used anti-diabetic drug with potential anti-tumor activity.

12 anti-PD-ligand 1 (L1) Abs for their optimal anti-tumor activity.

13 other mechanisms contribute to perifosine's anti-tumor activity.

14 perties, which give it immunosuppressant and anti-tumor activity.

15 tion of these enzymes has been shown to have anti-tumor activity.

16 rms of immunity contribute to complete apoA1 anti-tumor activity.

17 equired for an optimal alpha-GalCer-mediated anti-tumor activity.

18 r-expressed tumors can further enhance their anti-tumor activity.

19 rategy for producing targeted and long-lived anti-tumor activity.

20 reduced incidence of acute GvHD yet retained anti-tumor activity.

21 t to one favoring acute responses and potent anti-tumor activity.

22 is a transcription factor that has apoptotic anti-tumor activity.

23 ng investigated in clinical trials for their anti-tumor activities.

24 of MAP30, a plant protein with anti-HIV and anti-tumor activities.

25 pathway that contributes to MAP30's anti-HIV/anti-tumor activities.

26 pharmaceutical agents with antimicrobial and anti-tumor activities.

27 cargos to immune recipient cells, inhibiting anti-tumor activities.

28 ive anti-inflammatory, immunosuppressive and anti-tumor activities.

29 of them, show specific anti-inflammatory and anti-tumor activities.

30 e cytokines with potent immunomodulating and anti-tumor activities.

31 orated in DOPC nanoliposomes, we demonstrate anti-tumor activities.

32 ains of mice, yet retains full cytotoxic and anti-tumor activities.

33 nhibits MEK1/2 phosphorylation, and exhibits anti-tumor activities across multiple models carrying KR

34 olated death ligand that possesses selective anti-tumor activity against a number of cancer cell line

35 is a novel cytotoxic agent with exceptional anti-tumor activity against a range of human and murine

36 a topoisomerase I (TOP1) inhibitor, exhibits anti-tumor activity against a wide range of tumors.

37 NO-Cbl and Apo2L/TRAIL exerted synergistic anti-tumor activity against A375 xenografts.

38 quinol derivative that exhibits significant anti-tumor activity against human breast, colon, and ren

39 nces oral absorption of DIM-14 and increased anti-tumor activity against lung tumor models.

40 n effective strategy to enhance the avidity, anti-tumor activity and functional memory formation of T

41 of PA-L1-I207R and PA-U2-R200A showed potent anti-tumor activity and low toxicity, exceeding the perf

42 Anti-tumor activity and selectivity of Dp44mT in Pgp-exp

43 on of apoptosis by XK469 may account for its anti-tumor activity and such activity is required for th

44 We evaluated anti-tumor activity and toxic effect of an adenoviral ve

45 -malaria drug that has been shown to exhibit anti-tumor activity, and functional lysosomes are report

46 nd GM-CSF or IL-2 DNA resulted in equivalent anti-tumor activity as E2.

47 o of these inhibitors, PD98059 and TPCK, had anti-tumor activity as single agents in both zebrafish e

48 (HIF2A) is of central importance to miR-182 anti-tumor activity, as it results in enhanced therapy s

49 ase inhibitors is insufficient for effective anti-tumor activity because the reactivation of the ErbB

50 rus type 5 E1A protein (E1A) associates with anti-tumor activities by reversing the transformed pheno

51 ), a cell-permeable, small molecule that has anti-tumor activity, can also activate NOD1 and NOD2.

52 ing hCD19 resulted in significant additional anti-tumor activity, demonstrating the feasibility of ge

53 CLDC-based delivery also identified a novel anti-tumor activity for the metastasis suppressor gene C

54 A better understanding of how to uncouple anti-tumor activity from loss of self-tolerance is neces

55 ned delivery of these genes did not increase anti-tumor activity, further suggesting that each gene a

56 ccines designed to elicit CTL responses with anti-tumor activity has become a reality thanks to the i

57 Anti-tumor activity has been demonstrated with monoclona

58 r and molecular mechanisms of IL-12-mediated anti-tumor activity have been examined.

59 ble tool to simultaneously evaluate the drug anti-tumor activity, hepatotoxicity and pharmacokinetics

60 how that apoptosis plays a key role in their anti-tumor activities in colon cancer cells and xenograf

61 ng other IgG1 and IgG2 mAbs to DR4 for their anti-tumor activities in vivo.

62 cutaneous AIDS-KS tumors caused considerable anti-tumor activity in a dose-dependent manner, with hig

63 , our data prove that poly I:C has potential anti-tumor activity in a mouse model of established pulm

64 b, a proteasome inhibitor, shows substantial anti-tumor activity in a variety of tumor cell lines, is

65 dose-dependent in vivo CARM1 inhibition and anti-tumor activity in an MM xenograft model.

66 ermore, inhibitors of NF-kappaB demonstrated anti-tumor activity in androgen deprivation-resistant pr

67 A p53 rescue motif peptide exhibits an anti-tumor activity in cancer cell lines expressing wild

68 Consequently, Dp44mT has greater anti-tumor activity in drug-resistant relative to non-Pg

69 olecule inhibitors against EZH2 demonstrated anti-tumor activity in EZH2-mutated lymphomas and entere

70 R-2HG also displays anti-tumor activity in glioma.

71 nts targeting Her2 have not yet demonstrated anti-tumor activity in MIBC.

72 t antisense MDM2 inhibitors have significant anti-tumor activity in multiple human cancer models with

73 To gain insight into perifosine anti-tumor activity in neuroblastoma we have studied cha

74 antibody has recently been reported to have anti-tumor activity in preclinical models.

75 inds a unique CD38 epitope and showed strong anti-tumor activity in preclinical models.

76 available Notch-blocking agents are showing anti-tumor activity in preclinical studies, they are not

77 otein has membrane-disrupting properties and anti-tumor activity in several cancer animal models.

78 merging studies show that it displays potent anti-tumor activity in several human cancers.

79 ed at doses that have resulted in impressive anti-tumor activity in several types of refractory neopl

80 (Iressa) and erlotinib (Tarceva) have shown anti-tumor activity in the treatment of non-small cell l

81 kt membrane translocation and that API-1 has anti-tumor activity in vitro and in vivo and could be a

82 cells/tissues, leading to a higher level of anti-tumor activity in vitro and in vivo.

83 ), produces potent and highly CD30-selective anti-tumor activity in vitro and in vivo.

84 This may greatly improve TIL persistence and anti-tumor activity in vivo after adoptive transfer into

85 annoma cells in culture and displayed potent anti-tumor activity in vivo, impairing schwannoma develo

86 ff-target reactivity while maintaining their anti-tumor activity in vivo, thus showing that complete

87 lly stable in liver microsomes and displayed anti-tumor activity in xenograft mouse cancer models.

88 in vivo angiogenesis assays showed that this anti-tumor activity is due largely to the indirect targe

89 Their anti-tumor activity is further enhanced by in vivo co-st

90 that a potential mechanism of rhIL-2/rmIL-12 anti-tumor activity is the inhibition of neovascular gro

91 d the analogs as novel SHP-1 inhibitors with anti-tumor activity likely via an immune mechanism, supp

92 The nanobioconjugate exhibited marked anti-tumor activity manifested by significantly longer a

93 initially came to prominence because of its anti-tumor activity, most attention is now focused on it

94 ermore, the MMP-activated LT had very potent anti-tumor activity not only to human melanomas containi

95 which plays a mechanistic role in mediating anti-tumor activities of HER2-directed therapies.

96 Our results indicate that harnessing the anti-tumor activities of miR-182 via safe and robust del

97 anisms have been proposed to account for the anti-tumor activities of therapeutic antibodies, includi

98 sted that the antiproliferative and possibly anti-tumor activities of these compounds are linked to t

99 proaches discovered recently can augment the anti-tumor activities of TNFR antibodies by enhancing th

100 ify miR-498 as an important mediator for the anti-tumor activity of 1,25(OH)(2)D(3).

101 The anti-tumor activity of 5-FU has been attributed in part

102 a synthetic mimics significantly enhance the anti-tumor activity of all the above-mentioned anti-canc

103 implying a critical role for B cells in the anti-tumor activity of APCP.

104 ty in glioblastoma lines and potentiated the anti-tumor activity of both temozolomide and ionizing ra

105 rier to tumorigenesis and contributes to the anti-tumor activity of certain chemotherapeutic agents.

106 en used as a monotherapy, or may enhance the anti-tumor activity of chemotherapeutics, since constitu

107 novel insight into the mechanisms underlying anti-tumor activity of E1A, but also a rationale for the

108 ls with AT-101 can significantly enhance the anti-tumor activity of EGFRBi armed ATC through increase

109 Recent data demonstrating anti-tumor activity of FL suggest that this protein play

110 In the present study we analyzed the anti-tumor activity of human IL-1 homologue 4(IL-1H4; re

111 Although the anti-tumor activity of hyaluronan-oligosaccharides, a hy

112 ies also provide convincing evidence for the anti-tumor activity of I3C, however, the molecular mecha

113 Anti-tumor activity of IGF-Ir/tf is mediated through inh

114 The anti-tumor activity of IL-1H4 was abrogated in nude and

115 The anti-tumor activity of IPI-504 was tested as both a sing

116 g inhibition is the mechanistic basis of the anti-tumor activity of isoginkgetin.

117 ing cellular cytotoxicity and apoptosis, the anti-tumor activity of mAb's might also result from acti

118 lts demonstrated for the first time that the anti-tumor activity of megestrol acetate can be enhanced

119 We have previously demonstrated the anti-tumor activity of nitrosylcobalamin (NO-Cbl), an an

120 To evaluate the anti-tumor activity of p53-VP22 in vivo, we constructed

121 ion and support that phenformin improves the anti-tumor activity of PD-1 blockade immunotherapy in me

122 The anti-tumor activity of recombinant mAb's directed agains

123 Here, PHY906 is reported to enhance the anti-tumor activity of Sorafenib in nude mice bearing He

124 ge could counteract PHY906 to potentiate the anti-tumor activity of Sorafenib.

125 Our findings demonstrate in vivo anti-tumor activity of SSOs that modulate Bcl-x pre-mRNA

126 entional therapy and delineate mechanisms of anti-tumor activity of Thal and its potent analogs (immu

127 glioblastoma tumorigenesis, we explored the anti-tumor activity of the novel fusion protein EGF-SubA

128 tion because both the immunogenicity and the anti-tumor activity of the vaccine are blocked in mice d

129 sing and novel approach for potentiating the anti-tumor activity of therapeutic mAb against EGFR and

130 Anti-tumor activity of these antibodies was proved using

131 ion by GA may be a critical component of the anti-tumor activity of this drug.

132 The anti-tumor activity of TIR-199 was confirmed in hollow f

133 This study was designed to assess the anti-tumor activity of topotecan (TPT) in patients with

134 This study was designed to assess the anti-tumor activity of topotecan (TPT) in patients with

135 Long-term persistence and sustained anti-tumor activity of transferred CTL, as well as respo

136 r, the biparatopic ADC demonstrates superior anti-tumor activity over ado-trastuzumab emtansine (T-DM

137 ll depletion, which may underlie the lack of anti-tumor activity previously observed in pre-clinical

138 tion with E2A and cytE2A induced synergistic anti-tumor activity, supporting enhanced peptide present

139 dney tumor cell lines, with >250-fold higher anti-tumor activities than observed with the natural pro

140 cells expressing the CAR, providing broader anti-tumor activity that arises quickly after transplant

141 establish DMF as an NFkappaB inhibitor with anti-tumor activity that may add therapeutic value in th

142 -resistant metastatic melanoma patients show anti-tumor activity through B-cell depletion by anti-CD2

143 a novel mechanism(s) by which HNK exerts its anti-tumor activity through the inhibition of c-Met-Ras-

144 Anti-tumor activity was carried out in H1650 lung tumor

145 This anti-tumor activity was dependent on IFN-gamma and CD4(+

146 Anti-tumor activity was further enhanced by appending a

147 Encouraging anti-tumor activity was noted.

148 contrast, the anti-PD-L1 Abs show augmented anti-tumor activity when activating FcgammaR binding is

149 design of novel therapies exhibiting robust anti-tumor activity with limited toxicity.

150 complex microbial stimuli can elicit potent anti-tumor activity within the liver, promote cross-pres